- News
- Announcements
Announcements
Current & archive
Covid-19: HSS/ Horizon Scanning Living Document (v12 March 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 38 (January 2021)
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)
Fact Sheet No. 39 (January 2021)
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 40 (January2021)
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
Covid-19: HSS/ Horizon Scanning Living Document (v11 February 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Covid-19: HSS/ Horizon Scanning Living Document (v10 January 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our seven new HSO Fact Sheets.
Fact Sheet No. 31 (Dezember 2020)
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma
Fact Sheet No. 32 (Dezember 2020)
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer
Fact Sheet No. 33 (Dezember 2020)
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis
Fact Sheet No. 34 (Dezember 2020)
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer
Fact Sheet No. 35 (Dezember 2020)
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)
Fact Sheet No. 36 (Dezember 2020)
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
Fact Sheet No. 37 (Dezember 2020)
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer
Covid-19: HSS/ Horizon Scanning Living Document (v09 December 2020)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 28 (November 2020)
Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)
Fact Sheet No. 29 (November 2020)
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)
Fact Sheet No. 30 ((November 2020)
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer
Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II)
Recent evidence on the effectiveness of lung cancer screening with low dose computed tomography (LDCT), such as the National Lung Screening Trial (NLST) or the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON), seems to confirm a potential relative lung cancer mortality reduction (although not in overall mortality) from the LDCT-screening. Since then, a considerable body of new evidence also emerged on the cost-effectiveness of LDCT-screening for lung cancer. In this context, the present systematic review aimed to provide an update of the evidence on the cost-effectiveness, cost-utility and budget impact of LDCT lung cancer screening in adult persons without confirmed or suspected lung cancer but at elevated risk, with a special focus on the health economic methodologies.
Publication: HTA Project Report No. 132b: https://eprints.aihta.at/1283
Contact: Christian Ernst Heinrich Boehler, Sarah Wolf
Lung cancer screening in risk groups
Lung cancer is the fourth most frequently diagnosed cancer in the European Union. Risk factors for lung cancer include smoking in particular, family history, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and occupational or environmental exposure to radon, asbestos or fine particles. Low-dose computed tomography (LDCT) can be used for lung cancer screening, which is increasingly offered in routine clinical practice. Current evidence shows that screening for lung cancer with LDCT in (former) heavy smokers probably reduces lung cancer mortality, but results in little or no difference in overall mortality, compared with no screening.
Publication: HTA Project report No. 132a: http://eprints.aihta.at/1282/
Contact: Claudia Wild
